To systematically identify and compare mechanisms of resistance to PI3K versus AKT pathway inhibition, we performed genome-scale CRISPR knockout (KO) screens in PTEN-deficient BC cells in the presence of AKT and PI3Kβ inhibitors. This evidence concerns the gene PIK3CB and breast cancer.